RAD-140

RAD-140 (Testolone) is a selective androgen receptor modulator (SARM), not a peptide, being investigated for potential therapeutic applications in muscle wasting and breast cancer. SARMs are designed to selectively activate androgen receptors in muscle and bone while minimizing effects on reproductive organs, potentially offering anabolic benefits with fewer side effects than traditional androgens. Preclinical research demonstrates RAD-140 increases lean muscle mass, enhances strength, and may have neuroprotective properties. The compound has shown anti-tumor activity in androgen receptor-positive breast cancer models. Phase 1 clinical trials have evaluated safety in postmenopausal women with breast cancer. Despite being investigational and not approved for any medical use, RAD-140 is widely available in the supplement market and used for physique enhancement. The compound suppresses natural testosterone production, requires post-cycle therapy, and carries unknown long-term risks. RAD-140 is banned by WADA and most sports organizations. Liver toxicity has been reported in some users, highlighting the risks of unregulated use.

The only human trial is a small phase 1 oncology study in a specific patient population; there is no evidence of safety or efficacy for muscle-building use in healthy people, and liver enzyme elevations were frequent. It is not FDA approved and is prohibited in sport.

RAD-140 (testolone) is an oral, nonsteroidal selective androgen receptor modulator (SARM), not a peptide. In the phase 1 trial, doses of 50-150 mg once daily were evaluated; the half-life was ~44.7 hours, supporting once-daily dosing, and the MTD was 100 mg/day. AR engagement was confirmed via decreased SHBG and increased PSA. WADA banned.